Rosetta Biosoftware
NYSE : MRK

Rosetta Biosoftware

October 03, 2005 10:59 ET

Rosetta Biosoftware and Agendia to Deliver Diagnostic Utilities; Agendia Licenses the Rosetta Resolver System

SEATTLE and AMSTERDAM, The Netherlands--(CCNMatthews - Oct 3, 2005) -

Rosetta Biosoftware and Agendia today announced that the two organizations will work together to deliver novel diagnostics tools that will be made available in the Rosetta Resolver® system for gene expression data analysis. In order to enable this coordinated effort, Agendia licensed the Resolver system from Rosetta Biosoftware.

"As we are now approaching 10,000 microarray hybridizations associated with extensive clinical data, the Rosetta Resolver system is probably the only software product that can deal with the kind of analyses performed at our facilities. We are confident the Resolver system will significantly enhance our gene expression analysis-based diagnostic services," said Dr. Laura van't Veer, chief operating officer of Agendia. "Our objective is to use the Resolver system to develop and explore gene expression profiles in support of our clients' expanding clinical research programs. In addition, we would also like to incorporate Agendia's own diagnostics workflow into the system."

"The Resolver system's ability to support 21 CFR Part 11 compliance greatly assured us that it is our product of choice for a fully integrated diagnostics and research platform for gene expression data," added Prof. Dr. Rene Bernards, chief scientific officer of Agendia and project consultant.

"Rosetta Biosoftware and Agendia will enable interoperability between the Resolver system and Agendia's clinical and gene expression database to support Agendia's research and development of diagnostic products and services," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "Agendia's unparalleled expertise in the cancer diagnostics field adds significant value to our current and future business and research directions. Agendia's licensing of the Resolver system represents the first time Rosetta Biosoftware has signed an agreement with a company engaged in using gene expression to diagnose disease." Shevelenko added, "The Resolver system's flexibility and power enable it to seamlessly address new applications and functional areas, permitting Rosetta Biosoftware to continue to meet the diverse needs of life science research organizations."

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware and is distributed exclusively by Agilent Technologies.

About Agendia

Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test -- MammaPrint® -- that predicts the chance of breast cancer recurrence. Recently Agendia also added CupPrint® to its pipeline for the identification of Cancers of Unknown Primary. Agendia maintains close ties with the Netherlands Cancer Institute (NKI), ensuring access to the latest developments in cancer research. Next to the development of new cancer diagnostics, Agendia offers its expertise in finding new prospective gene expression profiles to companies focusing on new drug development in the area of oncology.

More information about Agendia BV is available at www.agendia.com.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are registered trademarks of Rosetta Inpharmatics LLC.

MammaPrint and CupPrint are registered trademarks of Agendia BV.

Contact Information

  • Rosetta Biosoftware
    Myra Ozaeta, 206-926-1288
    or
    Agendia BV
    Rene Bernards, +31 20 512 1952